Pharmaceutical Patents: Incentive for Research
Weakening patent protection or issuing compulsory licenses are not solutions for accelerating vaccine production. Long-term research incentives are crucial.
Neither weakening patent protection nor issuing compulsory licenses has accelerated the production of COVID-19 vaccines globally. Stakeholders argue that patents and licenses are essential for long-term innovation.
In the European Union, patent protection for pharmaceuticals can last up to 25 years. During this period, products are developed, approved, and marketed. Afterward, companies have an average of approximately 12 years to recoup their investments and generate profit.
Pharmaceutical research relies on stable frameworks that protect intellectual property. Long-term development processes involve investigating thousands of compounds, which can take over 13 years before an active substance is approved.
Rapid advancements, such as with mRNA vaccines, often build upon years of foundational research. Companies have developed technologies previously for other purposes, including cancer therapy, before applying them to COVID-19.